Trade Tracker: Bill Baruch buys Edwards Lifesciences
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Fiscal Year: January - December
Edwards Lifesciences Corporation (EW), listed on the NYSE, has a market capitalization of $41.79B. As of May 21, 2025, the stock is trading at $77.83 per share, offering investors a clear view of its current market value. Edwards Lifesciences Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 32.16, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Edwards Lifesciences Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Edwards Lifesciences Corporation (EW) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Edwards Lifesciences Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Edwards Lifesciences Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Edwards Lifesciences Corporation is 72.11, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Edwards Lifesciences Corporation (EW) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Edwards Lifesciences Corporation (EW) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Edwards Lifesciences Corporation (EW) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Edwards Lifesciences Corporation. To access the full SS Score, consider upgrading your subscription.
Edwards Lifesciences Corporation is a significant player in the industry sector, with a market capitalization of $41.79B and a competitive P/E ratio of 32.16. Investors should compare these metrics with industry peers to gauge whether Edwards Lifesciences Corporation is outperforming or underperforming within its sector.
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chi...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy...
Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Company Participants Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - ...
Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% ad...
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technolog...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and w...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of...
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology's (ACC) Annual Scientific Session & ...
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain und...
SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner an...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ulle...
On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all produc...
Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovig...
Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 bi...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, a...
Edwards Lifesciences Corporation EW shares are trading higher on Thursday.
Texas Pacific Land and Taiwan Semiconductor Manufacturing were top contributors for both the quarter and the year, showcasing strong earnings growth and strategic market positioning. Despite Texas Pac...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, ...
After analyzing weekly charts of all S&P 500 stocks, I found only 21 with “confidently optimistic” patterns, indicating a challenging market in 2025. My focus is on stocks with better odds of apprecia...
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and ce...
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporat...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 1.33B | Analyst x3 | |
2026 | 1.55B | 16.58% | Analyst x3 |
2027 | 1.74B | 12.44% | Analyst x2 |
2028 | 1.86B | 6.70% | Est @6.7% |
2029 | 1.95B | 5.01% | Est @5.0% |
2030 | 2.04B | 4.13% | Est @4.1% |
2031 | 2.11B | 3.51% | Est @3.5% |
2032 | 2.17B | 3.08% | Est @3.1% |
2033 | 2.23B | 2.58% | Est @2.6% |
2034 | 2.28B | 2.39% | Est @2.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 642.80M | 1.00 | 642.80M |
2024A | 289.90M | 1.00 | 289.90M |
2025E | 1.33B | 1.09 | 1.22B |
2026E | 1.55B | 1.18 | 1.31B |
2027E | 1.74B | 1.28 | 1.36B |
2028E | 1.86B | 1.39 | 1.33B |
2029E | 1.95B | 1.52 | 1.29B |
2030E | 2.04B | 1.65 | 1.24B |
2031E | 2.11B | 1.79 | 1.18B |
2032E | 2.17B | 1.94 | 1.12B |
2033E | 2.23B | 2.11 | 1.05B |
2034E | 2.28B | 2.30 | 993.19M |
Terminal | 37.90B | 2.30 | 16.50B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.